◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › 0-9 › 2297

Rainmed Medical Limited (2297) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Medical Devices · DATA UPDATED 2026-09-22

Rainmed Medical Limited (2297) operates in the Medical Devices industry and is headquartered in Suzhou, China with about 208 employees. Its market capitalization is roughly HK$224 million. In the fiscal year ended 2025-12-31, 2297 reported CNY 19M in revenue and (CNY 77M) in net income.

Rainmed Medical Limited operates as a vascular interventional surgical robotics company in China and internationally.

Interactive charts & full statements → Open the 2297 valuation workbench →

2297 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 19MCNY 40MCNY 73MCNY 84M—
Gross ProfitCNY 9MCNY 24MCNY 49MCNY 70M—
Operating Income (EBIT)(CNY 75M)(CNY 100M)(CNY 133M)(CNY 145M)—
Net Income(CNY 77M)(CNY 114M)(CNY 116M)(CNY 1.3B)—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2297 Free Cash Flow History

2297 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 546MCNY 463MCNY 573MCNY 690M—
Total LiabilitiesCNY 188MCNY 53MCNY 53MCNY 72M—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2297 viewer.

Other Companies in Medical Devices

← 2296All “0-9” companies2298 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.